The Motley Fool··Robert IzquierdoMaze CMO Dumps Entire Stock Position as Biotech Faces Clinical Uncertainty
Maze Therapeutics CMO Harold Bernstein sold 15,000 shares (~$442K) via pre-planned trading arrangement. Retains 237K options amid clinical-stage biotech challenges.
MAZEFDA approvalkidney disease